HPV-driven Cancer: from Epidemiology to the HPV-driven Tumor Board Proposal, Everything You Wanted to Know but Were Afraid to Ask

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2025 Mar 6

PMID 40048019

Authors

Daniela Alterio

Michal Gola

Mattia Zaffaroni

Maria Giulia Vincini

Carlo Guglielmo Cattaneo

Cynthia Aristei

Gabriella Macchia

Vitaliana De Sanctis

Francesca DeFelice

Affiliations

Soon will be listed here.

Abstract

Background: Human papilloma virus (HPV)-related cancers are well-known clinical entities in different body sites. Cervix, anus, and oropharynx are the most common tumors related to the virus infection. The aim of this work was to highlight similarities and differences among HPV-related cancers of different subsites.

Methods: The narrative review was focused on the following topics: (1) epidemiology, (2) prognostic factors, (3) treatment approaches, (4) radiomic analysis, (5) radiosensitivity, (6) de-escalation strategies. Common aspects as well as differences have been highlighted for cervical, anal and oropharyngeal HPV-related tumors.

Results: Common prognosticators in terms of patients characteristics (anemia, smoking habits), tumor histology (lymph node extracapsular extension) biological features (high circuating HPV DNA), blood cell immunomodulating response (high level of tumor-infiltrating lymphocytes and high neutrophil-to-lymphocyte ratio) as good parameters of radiosensitivity (radiosensitivity index RSI, and genomic adjusted radiation dose GARD) have been found among the analyzed tumor subsites. On the contrary, other aspects like treatment approaches (different RT techniques and doses), radiomic analysis and de-intensification strategies were found to be different among tumors.

Conclusion: HPV-related tumors have several common prognostic and predictive features that do not translate into common therapeutic approaches and de-intensification strategies. A better understanding of which factors are associated with a high risk of early recurrence or favourble clinical outcomes could help in guiding clinical assessment and screening activities and might improve efforts for precision medicine.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Szymonowicz K, Chen J . Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020; 17(4):864-878. PMC: 7721094. DOI: 10.20892/j.issn.2095-3941.2020.0370. View

Zhang Y, Qiu K, Ren J, Zhao Y, Cheng P . Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use. Signal Transduct Target Ther. 2025; 10(1):44. PMC: 11760352. DOI: 10.1038/s41392-024-02083-w. View

Chaturvedi A . Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010; 46(4 Suppl):S20-6. DOI: 10.1016/j.jadohealth.2010.01.016. View

de Martel C, Plummer M, Vignat J, Franceschi S . Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017; 141(4):664-670. PMC: 5520228. DOI: 10.1002/ijc.30716. View

Alemany L, Cubilla A, Halec G, Kasamatsu E, Quiros B, Masferrer E . Role of Human Papillomavirus in Penile Carcinomas Worldwide. Eur Urol. 2016; 69(5):953-61. DOI: 10.1016/j.eururo.2015.12.007. View

Castellsague X, Alemany L, Quer M, Halec G, Quiros B, Tous S . HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Natl Cancer Inst. 2016; 108(6):djv403. DOI: 10.1093/jnci/djv403. View

Serrano B, de Sanjose S, Tous S, Quiros B, Munoz N, Bosch X . Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015; 51(13):1732-41. DOI: 10.1016/j.ejca.2015.06.001. View

Bhatla N, Aoki D, Sharma D, Sankaranarayanan R . Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021; 155 Suppl 1:28-44. PMC: 9298213. DOI: 10.1002/ijgo.13865. View

10.

Senapati R, Senapati N, Dwibedi B . Molecular mechanisms of HPV mediated neoplastic progression. Infect Agent Cancer. 2016; 11:59. PMC: 5123406. DOI: 10.1186/s13027-016-0107-4. View

11.

Mehanna H, Bryant T, Babrah J, Louie K, Bryant J, Spruce R . Human Papillomavirus (HPV) Vaccine Effectiveness and Potential Herd Immunity for Reducing Oncogenic Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-sectional Study. Clin Infect Dis. 2018; 69(8):1296-1302. PMC: 6763631. DOI: 10.1093/cid/ciy1081. View

12.

Torres-Roman J, Azanedo D, Ruiz E, Avilez J, Malaga G, Machicado C . Human papillomavirus-associated oropharyngeal cancer: Prioritizing preventive policies in males. Oral Oncol. 2017; 69:129-130. DOI: 10.1016/j.oraloncology.2017.04.013. View

13.

De Felice F, Polimeni A, Tombolini V . Human papillomavirus (HPV) vaccine and HPV-related head and neck cancer: What's next?. Oral Oncol. 2019; 93:125-126. DOI: 10.1016/j.oraloncology.2019.04.001. View

14.

Tabatabaeian H, Bai Y, Huang R, Chaurasia A, Darido C . Navigating therapeutic strategies: HPV classification in head and neck cancer. Br J Cancer. 2024; 131(2):220-230. PMC: 11263586. DOI: 10.1038/s41416-024-02655-1. View

15.

Litwin T, Clarke M, Dean M, Wentzensen N . Somatic Host Cell Alterations in HPV Carcinogenesis. Viruses. 2017; 9(8). PMC: 5580463. DOI: 10.3390/v9080206. View

16.

Bishop A, Allen P, Klopp A, Meyer L, Eifel P . Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated?. Int J Radiat Oncol Biol Phys. 2014; 91(1):196-205. DOI: 10.1016/j.ijrobp.2014.09.023. View

17.

Wang X, Xu J, Zhang H, Qu P . The effect of albumin and hemoglobin levels on the prognosis of early-stage cervical cancer: a prospective, single-center-based cohort study. BMC Womens Health. 2023; 23(1):553. PMC: 10598933. DOI: 10.1186/s12905-023-02713-5. View

18.

Serkies K, Badzio A, Jassem J . Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy. Acta Oncol. 2006; 45(6):695-701. DOI: 10.1080/02841860600833160. View

19.

Barkati M, Fortin I, Mileshkin L, Bernshaw D, Carrier J, Narayan K . Hemoglobin level in cervical cancer: a surrogate for an infiltrative phenotype. Int J Gynecol Cancer. 2013; 23(4):724-9. DOI: 10.1097/IGC.0b013e31828a0623. View

20.

Horn L, Hentschel B, Galle D, Bilek K . Extracapsular extension of pelvic lymph node metastases is of prognostic value in carcinoma of the cervix uteri. Gynecol Oncol. 2007; 108(1):63-7. DOI: 10.1016/j.ygyno.2007.08.086. View